Dendreon picks CMO PharmaCell to make Provenge in Europe

Dutch CMO PharmaCell has inked a deal with the struggling Dendreon ($DNDN) to manufacture its prostate cancer drug Provenge in Europe. The injection won European approval in September, and the agreement is part of a two-year relationship between the two companies. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.